Smyth, Penelope http://orcid.org/0000-0003-1174-4577
Watson, Kaitlyn E. http://orcid.org/0000-0001-6617-9398
Al Hamarneh, Yazid N.
Tsuyuki, Ross T. http://orcid.org/0000-0002-3724-598X
Article History
Received: 22 February 2022
Accepted: 19 July 2022
First Online: 25 July 2022
Declarations
:
: The study was performed in accordance with the Declaration of Helsinki, and was approved by the Health Research Ethics Boards of the University of Alberta (approval number Pro00069595). This trial was registered retrospectively on ExternalRef removed (ExternalRef removed Identifier: NCT04388592, 14/05/2020).Informed consent was obtained from all participants to participate in the study, prior to being randomized to participate within the study, and before completing baseline measures.
: N/A
: P. Smyth has received grant support through CIHR and the MS Society of Canada and is a co-investigator in a study funded by an unrestricted research grant from Biogen pharmaceuticals. She has consulted on advisory boards for Novartis Pharmaceuticals, Roche Canada, Biogen Idec Pharmaceuticals, Sanofi-Genzyme Pharmaceutical, Bristol-Myers-Squibb Pharmaceuticals, Alexion Pharmaceuticals, Alberta Blue Cross and the Short-Term Exceptional Drug Therapy Program for Alberta Health Services.K. Watson has no conflicts of interest to declare.Y. Hamarneh has no conflicts of interest to declare.R. Tsuyuki has done consulting for Emergent BioSolutions and Shoppers Drug Mart and has received investigator-initiated research grants from Sanofi, Merck, AstraZeneca, and Pfizer.